Molecular diagnosis of Alzheimer Disease

• US 5,015,570 A
• Filed: 05/13/1988
• Issued: 05/14/1991
• Est. Priority Date: 05/13/1988
• Status: Expired due to Fees

• Current Assignee: Molecular Therapeutics, Inc.
• Original Assignee: Molecular Therapeutics, Inc.
• Inventors: Unterbeck, Axel J., Scangos, George A., Kamarck, Michael E., Rae, Peter M. M.
• Primary Examiner(s): Wax, Robert A.
• Assistant Examiner(s): Marschel, Ardin H.
• Application Number:
  US07/194,053
• Time in Patent Office: 1,096 Days
• Field of Search: 435/6, 436/501, 436/811, 536/27, 935/19, 935/77, 935/78
• US Class Current: 435/5
• CPC Class Codes: C12Q 1/6827 for detection of mutation or polymorphism
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: Y10S 436/811 Test for named disease, body condition or organ function

Abstract

A method for diagnosing Alzheimer Disease or a predisposition to develop Alzheimer Disease in an individual, by determining the presence of an alteration in the normal base sequence of the 24 base pairs appearing at the end of the APC coding sequence of the preAPC gene, or in the normal base sequence of the corresponding mRNA, in the DNA or RNA or such individual. The method detects the presence of a frameshift mutation in the preAPC gene postulated to result in the synthesis of the APC protein. Accumulation of APC protein in the brain is a phenomenon of Alzheimer Disease. A variety of nucleic acid hybridization techniques are applicable to the determination of an alteration in the preAPC gene sequence of interest.

Claims

1. A method for diagnosing Alzheimer Disease or a predisposition to develop Alzheimer Disease in an individual, comprising the step of determining the presence of an alteration in the normal DNA base sequence

View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

2. The method of claim 1 wherein such individual is presymptomatic for Alzheimer Disease and the presence of an alteration in said normal DNA base sequence, or in its complementary DNA or RNA sequences, indicates a risk that such individual will develop the disease.

3. The method of claim 1 wherein the presence of an alteration in said normal sequences is determined by obtaining sample DNA or RNA from said individual in single stranded form, hybridizing the single stranded sample DNA or RNA with an oligonucleotide probe comprising the DNA base sequence

4. The method of claim 3 wherein said oligonucleotide probe consists of less than 50 nucleotides and includes the 24 nucleotide DNA base sequence

5. The method of claim 4 wherein said oligonucleotide probe consists essentially of less than 30 nucleotides.

6. The method of claim 4 wherein said oligonucleotide probe consists essentially of only said 24 nucleotide base sequence.

7. The method of claim 3 wherein imperfect homology in said resulting hybrids is determined by exposing the hybrids to a single stranded specific nuclease and detecting the presence or absence of hybrid fragments.

8. The method of claim 1 wherein the presence of an alteration in said normal sequences is determined by obtaining sample DNA or RNA from said individual in single stranded form, hybridizing the single stranded sample DNA or RNA with an oligonucleotide probe having a base sequence of at least 10 nucleotides homologous with the DNA sequence of the preAPC gene having a mutation in said normal DNA base sequence or in its complementary DNA or RNA sequence, and analyzing resulting hybrids for perfect homology.

9. The method of claim 8 wherein said oligonucleotide probe consists essentially of up to 24 nucleotides corresponding to the base sequence of said mutated form of the normal DNA base sequence or its complementary DNA or RNA sequences.

10. The method of claim 1 wherein the sample is genomic DNA.

11. The method of claim 1 wherein the sample is mRNA.

12. An oligonucleotide probe for use in the diagnosis of Alzheimer Disease or a predisposition to develop Alzheimer Disease, consisting essentially of less than 50 nucleotides and including the 24 nucleotide DNA base sequence

View Dependent Claims (13, 14, 15, 16)

13. The probe of claim 12 consisting essentially of less than 30 nucleotides.

14. The probe of claim 12 consisting essentially of only said 24 nucleotide base sequence.

15. The probe of claim 12 which additionally comprises a label.

16. The probe of claim 15 wherein said label is a radioactive isotope, a fluorescer, a chemiluminescer, or a specifically bindable ligand.

17. An oligonucleotide probe for use in the diagnosis of Alzheimer Disease or a predisposition to develop Alzheimer Disease, consisting essentially of at least 10 nucleotides whose base sequence is homologous with the DNA sequence of the preAPC gene having a mutation in the 24 nucleotide sequence

View Dependent Claims (18, 19, 20)

18. The probe of claim 17 consisting essentially of up to 24 nucleotides corresponding to the base sequence of said mutated DNA sequence or its complementary DNA or RNA sequences.

19. The probe of claim 17 which additionally comprises a label.

20. The probe of claim 19 wherein said label is a radioactive isotope, a fluorescer, a chemiluminescer, or a specifically bindable ligand.